

# Preclinical development of a bispecific $\alpha$ PD-1/IL-2v immunotherapy with enhanced TME selectivity and safety via modulated IL-2R $\gamma$ affinity

MustBio



ONCOLOGY	Preclinical
Product Type	Recombinant protein (fusion protein)
Indication	Solid tumor
Target	PD-1, IL-2 receptor in activated T cells
MoA (Mechanism of Action)	TME-selective T cell activation via cis-acting of $\alpha$ PD-1 and non- $\alpha/\gamma$ -attenuated IL-2 → Potent anti-tumor efficacy with minimized systemic effects
Competitiveness	<ul style="list-style-type: none"> <li>• TME selective T cell activation and expansion</li> <li>• Potent anti-tumor efficacy against ICI –resistant models</li> <li>• Wide safety margin observed in diverse animal models</li> </ul>
Development Stage	Preclinical
Route of Administration	Intravenous